Monday, November 23, 2026

Concord Biotech Q2 profit slides 34%; board clears new ventures

Date:

Concord Biotech Ltd on Thursday, November 13, reported a 33.6% year-on-year decline in its net profit at ₹63.6 crore for Q2FY26, compared to ₹95.7 crore in the same period last year.

The company’s revenue also declined 20.4% to ₹247.1 crore from ₹310.2 crore.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) fell 35.3% to ₹88.4 crore. The operating margin slipped to 35.8% from 44% a year ago.

The company’s board has approved a proposal to acquire 100% equity in Celliimune Biotech Pvt Ltd, marking a strategic expansion move in the biotech segment, stated the company’s exchange filing.

Additionally, the board cleared an investment of up to ₹10 crore in a captive hybrid solar power project for its Limbasi plant, reinforcing the company’s commitment to sustainable operations.

Shares of Concord Biotech Ltd ended marginally higher on Thursday, November 13, by 0.04% at ₹1,463.80 on the NSE.

Also Read: TVS Supply Chain Q2 Results | Net profit spikes 54% on cost efficiency, strong execution

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

CLSA sees better US-India trade outlook; expects Fed and RBI to raise rates in December

The US is likely to push ahead with trade...

‘Trump has cost us’: After midterm losses, MAGA asks if it’s over

As Republicans faced a nationwide drubbing in Tuesday’s midterm...

Prashant Jain sees 12-15% annual returns from Indian equities over 3-5 years

Question We've had a very painful period for the equity...

Raamdeo Agrawal sees FIIs return as earnings improve and valuations turn attractive

Question Looking at the valuation compression across the market, are...